Comparison of Systemic Inflammatory Parameters with Anatomical Pathology Results in Differentiating Benign Prostatic Hyperplasia with and without Inflammation: Cross-Sectional Analytics
DOI:
https://doi.org/10.37287/ijghr.v8i3.1732Keywords:
benign prostatic hyperplasia, hematologic profile, inflammatory biomarkers, neutrophil-to-lymphocyte ratio, systemic inflammation indexAbstract
Chronic inflammation plays an important role in pathogenesisbenign prostatic hyperplasia (BPH). Anatomic pathology examination is the standard for detecting prostate inflammation, but it is invasive. Systemic inflammation parameters based on peripheral blood counts have the potential to be non-invasive biomarkers. Comparing inflammatory parameters based on peripheral blood counts NLR, PLR, MLR, SII and SIRI with Anatomical Pathology results in comparing BPH with and without inflammation. This research is an analytical cross-sectional study in BPH patients with and without inflammation based on the results of Anatomical Pathology. A total of 334 patients were included in this study, and the sampling technique used was consecutive sampling. Parametersneutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), systemic immune-inflammation index (SII), andsystemic inflammatory response index (SIRI) were analyzed and compared between groups. AnalysisReceiver Operating Characteristic (ROC) is used to determine the valuecut-off optimal. The median age of patients was relatively homogeneous. In the BPH group with inflammation, Total leukocyte count, absolute neutrophil count, and absolute monocyte count were higher, while absolute lymphocyte count was lower. All systemic inflammation parameters (NLR, PLR, MLR, SII, and SIRI) were significantly higher in the inflammation group (p < 0.001). SII showed the highest AUC value (0.840), followed by NLR (0.829) and SIRI (0.822). Based on our research, it can be concluded that systemic inflammatory parameters have the potential to be used as non-invasive biomarkers to determine whether a person has BPH with inflammation or not.
References
Ahmed, R., Hamdy, O., & Awad, R. M. (2023). Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network. Scientific Reports, 13(1), 14801. https://doi.org/10.1038/s41598-023-41781-3
Cai, T., Santi, R., Tamanini, I., Galli, I. C., Perletti, G., & Bjerklund Johansen, T. E. (2019). Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. International Journal of Molecular Sciences, 20(15), 3833.
Fibbi, B., Penna, G., Morelli, A., Adorini, L., & Maggi, M. (2010). Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. International Journal of Andrology, 33(3), 475–488.
Ficarra, V., Rossanese, M., Zazzara, M., Giannarini, G., Abbinante, M., & Bartoletti, R. (2014). The role of inflammation in lower urinary tract symptoms due to benign prostatic hyperplasia and its potential impact on medical therapy. Current Urology Reports, 15(12), 463.
Jiang, Y. H., Lee, J., Kuo, H. C., & Wu, Y. H. (2025). Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia. International Journal of Molecular Sciences, 26(13), 6516.
Kang, J. Y., Choi, J. D., Cho, J. M., Yoo, T. K., Park, Y. W., & Lee, J. H. (2021). Association of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Lymphocyte-to-Monocyte Ratio with Benign Prostatic Hyperplasia. Urologia Internationalis, 105(9–10), 811–816. https://doi.org/10.1159/000512894
Ozer, K., Horsanali, M. O., Gorgel, S. N., Horsanali, B. O., & Ozbek, E. (2017). Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urologia Internationalis, 98(4), 466–471.
Robert, G., Descazeaud, A., Nicolaiew, N., Terry, S., Sirab, N., & Vacherot, F. (2009). Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. The Prostate, 69(16), 1774–1780.
Shi, C., Cao, H., Zeng, G., Yang, L., & Wang, Y. (2024). The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia. PLOS ONE, 19(7), e0306860. https://doi.org/10.1371/journal.pone.0306860
Song, Y., Gu, Y., Guo, H., Yang, H., Wang, X., Wu, H., Wang, A., Wang, H., Zhang, Q., Liu, L., Meng, G., Liu, B., & Niu, K. (2023). Association Between Neutrophil-to-Lymphocyte Ratio and Benign Prostatic Hyperplasia. Journal of Inflammation Research, 16, 4857–4866. https://doi.org/10.2147/JIR.S431049
Vuichoud, C., & Loughlin, K. R. (2015). Benign prostatic hyperplasia: epidemiology, economics and evaluation. Canadian Journal of Urology, 22(Suppl 1), 1–6.
Wang, Y., Wang, J., Liu, J., & Zhu, H. (2024). Immune-related diagnostic markers for benign prostatic hyperplasia and their potential as drug targets. Frontiers in Immunology, 15, 1516362.
Wu, Y., Sheng, J., Liu, X., Huang, Y., Zhang, Y., & Feng, N. (2025). The relationship between immune-inflammatory indexes and the severity of lower urinary tract symptoms/benign prostatic hyperplasia. Journal of Inflammation Research, 18(1), 8509–8523.
Xiang, J., Zheng, Y., Chen, D., Zeng, Y., Zhang, J., & Chang, D. (2025). The pathogenesis of benign prostatic hyperplasia and the roles of Prdx3, oxidative stress, pyroptosis and autophagy: a review. Frontiers in Oncology, 15, 1579539.
Yang, Y., Xu, Y., Lu, P., Zhou, H., Yang, M., & Xiang, L. (2023). The prognostic value of monocyte-to-lymphocyte ratio in peritoneal dialysis patients. European Journal of Medical Research, 28(1), 152.
Zahorec, R. (2021). Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratislava Medical Journal, 122(7), 474–488.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
